Monotherapy with either anti–programed death 1 (anti–PD-1) antibody (RMP1-14) or APR-246 led to minimal tumor control in the B16 melanoma model (Figure 1D and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI148141DS1). The gene discussed is PDCD1; the disease is melanoma.